Vinge advises Ramirent AB in connection with its acquisition of JIAB Hyrcenter (consisting of the companies JIAB Hyrcenter AB and JIAB Boden AB). Ramirent thereby further strengthens its position in Norrbotten and as the largest machine rental company in Sweden.
Vinge has advised Svea Bank AB (the “Company”) in connection with its issuance of additional tier 1 capital (AT1) of SEK 300 million to optimise its capital structure.
Vinge has advised Danske Bank A/S, Danmark, Sverige Filial in connection with the signing of a new SEK 750 million credit facility for Svenska Retursystem Aktiebolag.
Vinge has advised Samhällsbyggnadsbolaget i Norden AB (publ) (”SBB”) in connection with the distribution of the shares in Neobo Fastigheter AB (publ) (”Neobo”) to the A and B shareholders in SBB. The resolution on the distribution was adopted at the Extraordinary General Meeting of SBB on 21 December 2022 and the distribution was carried out on 30 December 2022.
Vinge has advised Sandvik AB (publ) and Sandvik Treasury AB (publ) in connection with the entry into of a EUR 500 million loan agreement with the European Investment Bank (EIB). The loan will support Sandvik’s investments in research and development (R&D), which include advanced solutions in component manufacturing as well as solutions for electrification and automation in mining and infrastructure.
Vinge has advised Svenska Handelsbanken in connection with a SEK 500 million sustainability linked revolving credit facility with Byggmax Group AB (publ) as borrower.
Vinge advises Samhällsbyggnadsbolaget i Norden AB (publ) ("SBB") in connection with its sale of stake in its social infrastructure portfolio for public education to Brookfield for SEK 9.2 billion. The transaction also includes earn out payments up to SEK 1.2 billion.
The loan agreement with the European Investment Bank (EIB) grants Oncopeptides access to a renewed unsecured loan facility of up to EUR 30 million. The loan facility agreement is divided into three tranches, each with a maturity of five years, which will become available if the company, inter alia, satisfies certain milestones related to the ongoing commercialization of Pepaxti® in Europe and a potential relaunch of Pepaxto® in the US. In connection with the loan agreement, Oncopeptides has entered into a renewed warrant agreement with the EIB, entitling the EIB to warrants in the company should the company draw on the loan facility.
Vinge advises Axcel VI and the Currentum Group in connection with the acquisitions of Holmströms Rör AB, Holmströms Rör i Ängelholm AB and Holmströms Rör Syd Väst AB.
Vinge has advised Luossavaara-Kiirunavaara AB (publ) (“LKAB”) in connection with its investment in, REEtec Holding AS (“REEtec”). LKAB invests in the financing round, that totals NOK 1.2 billion, to become the largest shareholder of REEtec.
Vinge has advised STARK Group in connection with its acquisition of the Nordic tiles actor FagFlis Group with its Swedish operation FF Kakel AB. The group has conducted operations since 1981 and includes, in addition to the Swedish stores, approximately 30 facilities in Norway with total turnover of approximately NOK 750 million.
